Education
About Us
Working with TipRanks
Follow Us
Altamira Therapeutics (CYTOF)
OTHER OTC:CYTOF
RESEARCH TOOLSreports
Earnings Data
Report Date
Sep 03, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
―Last Year’s EPS
-1.79Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Date:Apr 30, 2025
|% Change Since: 25.00%
|Next Earnings Date:Sep 03, 2025
Earnings Call Sentiment|Neutral
Altamira showed significant progress in its RNA delivery business with new partnerships and patent filings, while overcoming setbacks such as Nasdaq delisting and increased net loss. The strategy to involve private equity investors and spin-off RNA delivery activities indicates proactive steps for future growth.Company Guidance
During the Altamira Therapeutics' full-year 2024 financial results and business update call, the company provided several key metrics and strategic insights. The operating loss from continuing operations increased slightly from $6.6 million in 2023 to $6.9 million in 2024. Research and development expenses rose to $3.7 million from $3.4 million the previous year, whereas general and administrative expenses decreased to $3.2 million from $3.5 million. Notably, net finance expenses dropped significantly from $1.5 million to $0.8 million. The net loss for 2024 was reported at $8.5 million, with a cash usage reduction in operations from $12.8 million in 2023 to $6.1 million in 2024. Cash and cash equivalents increased to $1 million by year-end. The company anticipates a reduction in operating expenses following the partial spin-off of its RNA delivery subsidiary, ATAG, and seeks to fund future operations through existing cash, private equity, and strategic partnerships.RNA Delivery Business Momentum
Altamira gained 2 new partners for its xPhore platform and demonstrated its versatility with circular RNA, opening new business opportunities.
New Collaborations
Added a new collaboration agreement with a company in the radiopharmaceutical sector, expanding opportunities in cancer treatment.
Bentrio Nasal Spray Market Expansion
Expecting marketing approval for Bentrio in Mainland China, and received a patent for its composition in the U.S., providing protection up to 2040.
Decreased Cash Used in Operations
Cash used in operations decreased from $12.8 million in 2023 to $6.1 million in 2024.
Patent Application for CycloPhore
Filed a provisional patent application for CycloPhore with the U.S. Patent Office, highlighting its potential for circular RNA.
CYTOF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CYTOF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 30, 2025 | $0.08 | $0.09 | +12.50% |
Sep 24, 2024 | $0.67 | $0.70 | +4.48% |
Apr 10, 2024 | $1.86 | $2.00 | +7.53% |
Sep 12, 2023 | $6.80 | $6.39 | -6.03% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Altamira Therapeutics (CYTOF) report earnings?
Altamira Therapeutics (CYTOF) is schdueled to report earning on Sep 03, 2025, TBA Not Confirmed.
What is Altamira Therapeutics (CYTOF) earnings time?
Altamira Therapeutics (CYTOF) earnings time is at Sep 03, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CYTOF EPS forecast?
Currently, no data Available